(Total Views: 360)
Posted On: 05/14/2018 12:04:32 PM
Post# of 72447
Drano, Great article.
"$111 million up front to AurKa Pharma with another $465 million in milestones" = $575M for a cancer drug "showing promise" in a Phase 1 trail. (Basically where K was in 2012)
The deal comes just four days after Lilly $LLY announced it had acquired Armo BioSciences $ARMO for $1.6 billion in cash.
Kevetrin is worth many multiples more than these 2 examples and as investors we will benefit initially with IPIX monetizing investments in P and B very soon with K not too far behind.
"$111 million up front to AurKa Pharma with another $465 million in milestones" = $575M for a cancer drug "showing promise" in a Phase 1 trail. (Basically where K was in 2012)
The deal comes just four days after Lilly $LLY announced it had acquired Armo BioSciences $ARMO for $1.6 billion in cash.
Kevetrin is worth many multiples more than these 2 examples and as investors we will benefit initially with IPIX monetizing investments in P and B very soon with K not too far behind.
(4)
(0)
